Chairperson, those are too many questions in one question. The first one is about counselling; the second one is about dual therapy; and the last one is about the opt-out approach. I don't know which question the member wants me to answer. But let me take this opportunity, with regard to dual therapy - and I think this is a golden opportunity for me - to address the House on this matter. I do so because out there, particularly by the opposition parties, there is a notion that this government does not want to provide dual therapy. There is a question coming and we will address this in more detail.
However, I just want to remind all of us that it was this government and through this Minister who, in the first instance, asked the question: Why mono therapy for pregnant women? Are we not discriminating against them instead of giving them dual or triple therapy? Everybody was: give nevirapine, nevirapine, nevirapine. Now everybody is saying, "No nevirapine. Nevirapine is dangerous dual therapy." We could have gone a long way if we had been listened to as this government at all on the approaches that we were taking in order to ensure that we protect the women of this country. Thank you. [Applause.]